Shannon Kelley serves as the Executive Vice President and Chief Legal Counsel at Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on developing innovative therapies for non-alcoholic steatohepatitis (NASH). With a robust legal background spanning over two decades, Kelley brings a wealth of experience to her role, ensuring that Madrigal's operations adhere to the highest standards of regulatory compliance and corporate governance. Prior to joining Madrigal, Kelley held significant positions at leading pharmaceutical and biotechnology firms, where she honed her expertise in intellectual property law, corporate transactions, and regulatory affairs. At Madrigal Pharmaceuticals, Kelley is instrumental in navigating the complex legal landscape of drug development and commercialization. Her strategic oversight has been crucial in advancing the company's lead candidate, resmetirom, through clinical trials and towards potential market approval. Kelley's leadership extends beyond legal matters; she plays a key role in shaping the company's strategic direction, collaborating closely with the executive team to drive growth and innovation. Her commitment to excellence and ethical standards has earned her respect within the industry and among her colleagues at Madrigal. Kelley's professional achievements are complemented by her active involvement in industry associations and her contributions to legal scholarship in the life sciences sector. She frequently speaks at conferences and contributes to publications, sharing insights on the evolving regulatory environment and its impact on pharmaceutical innovation. Her dedication to fostering a culture of compliance and integrity at Madrigal has been pivotal in positioning the company as a leader in the fight against NASH, underscoring her invaluable role in the organization's success.